Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease

Ali Hassan Daghir Janabi

DOI: 10.4103/jmss.JMSS_25_20

Abstract


Background: The severe acute respiratory syndrome-like disease coronavirus disease 2019 (COVID-19) is a disastrous global pandemic with 16,288,490 infected cases and 649,884 deaths. Until now, no effective treatments are found. Methods: The virus uses the 3-chymotrypsin-like protease for inducing the activity of the viral polyproteins and the spike (S) glycoprotein for human cell entry through the human angiotensin-converting enzyme 2 receptor. Blocking the active binding sites of these molecules might be beneficial for decreasing the activity of the virus and suppressing the viral entry to the human cells. Here, docking methods were used to identify a group of ligands may perform the blocking operations. Results: The results revealed the strongest binding affinities, sorted high to low, for tadalafil (Cialis) (phosphodiesterase type 5 inhibitor, tirofiban (antiplatelet), paraxanthine (central nervous system stimulant), dexamethasone, gentian violet cation (triphenylmethane), salbutamol, and amlodipine (calcium channel blocker). Conclusions: These substances may provide vital help for further clinical investigation in fighting against the current global pandemic of the COVID-19.

Keywords


Cialis, coronavirus disease 2019, dexamethasone, ligands, salbutamol, severe acute respiratory syndrome-coronavirus 2

Full Text:

PDF

References


Worldometer. Coronavirus Cases. Worldometer; 2020. p. 1-22. Available from: https://www.worldometers.info/coronavirus/coronavirus-cases/#daily-cases. [Last accessed on 2020 Apr 04].

Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediat 2020;87:281.

Mackenzie JS, Smith DW. COVID-19: A novel zoonotic disease caused by a oronavirus from China: What we know and what we don't. Microbiol Aust 2020;41:45.

Mirzaei M, Harismah K, Da'I M, Salarrezaei E, Roshandel Z. Screening efficacy of available HIV protease inhibitors on COVID-19 protease. Mil Med 2020;22:100-7.

Harismah KM. Favipiravir: Structural analysis and activity against COVID-19. Adv J Chem B 2020;2:55-60.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-9.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.

Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020;525:135-40.

Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chin Med J (Engl) 2020;133:1015-24.

Yang XL, Hu B, Wang B, Wang MN, Zhang Q, Zhang W, et al. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. Virol 2015;90:3253-6.

Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 2018;14:e1007236.

Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4.

Li F, Li W, Farzan M, Harrison SC. Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (80-) 2005;309:1864-8.

Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, et al. Erratum to: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep 2018;8:15701.

Ge XY, Li JL, Yang X Lou, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013;503:535-8.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020;181:281-292.e6.

Thiel V, Ivanov KA, Putics Á, Hertzig T, Schelle B, Bayer S, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J General Virol 2003;84:2305-15.

The PyMOL Molecular Graphics System. No Title. Schrödinger, LLC.; 2020. Available from: https://pymol.org. [Last accessed on 2020 Jul 27].

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.

Macchiagodena M, Pagliai M, Procacci P. Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling; 2020. Available from: http://arxiv.org/abs/2002.09937. [Last accessed on 2020 Apr 04].

Mirzaei. M. Science and engineering in silico. Adv J Sci Eng 2020;1:1-2.

Abyar Ghamsari P, Samadizadeh MM. Cytidine derivatives as inhibitors of methyltransfer ase enzyme. Eurasian Chem Commun 2019;1:310-17.

Alidoosti ZS. Comparative examination of moclobemide, tranylcypromine, phenelzine and isocarboxazid for monoamine oxidase-a inhibition. Adv Chem B 2019;1:23-8.

Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25:2000180.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). StatPearls 202. NCBI Bookshelf ID: NBK554776 PMID: 32150360.

Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ 2020;369:m1313.

Coward RM, Carson CC. Tadalafil in the Treatment of Erectile Dysfunction. Ther Clin Risk Manag 2008;4:1315-30.

Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Ame 2005;32:379-95.

Carson CC. Phosphodiesterase Type 5 inhibitors: State of the therapeutic class. Urol Clin North Am 2007;32:507-15.

Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci U S A 2002;99:4061-6.

Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: An evidence-based review. Core Evid 2015;10:99-109.

Juwana YB, Suryapranata H, Ottervanger JP, Van'T Hof AW. Tirofiban for myocardial infarction. Expert Opinion Pharmacother 2010;34:861-6.

Bakker P, Van Doorne H, Gooskens V, Wieringa NF. Activity of gentian violet and brilliant green against some microorganisms associated with skin infection. Int J Dermatol 1992;31:210-3.

Maley AM, Arbiser JL. Gentian violet: A 19th Century Drug Re-emerges in the 21st Century. Exp Dermatol 2013;22:775–80.

Bhandarkar SS, MacKelfresh J, Fried L, Arbiser JL. Targeted therapy of oral hairy leukoplakia with gentian violet. Am Acad Dermatol 2008;58:711-2.

Aljofan M, Sganga ML, Lo MK, Rootes CL, Porotto M, Meyer AG, et al. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. Virol J 2009;6:187.

Munson J, Bonner M, Fried L, Hofmekler J, Arbiser J, Bellamkonda R. Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle 2013;12:2200-9.

Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 2012;4:127ra36.

McAllister CS, Ansaldi D, Growcott EJ, Zhong Y, Quackenbush D, Wolff KC, et al. Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling. Virology 2020;540:195-206.


Refbacks

  • There are currently no refbacks.


 

  https://e-rasaneh.ir/Certificate/22728

https://e-rasaneh.ir/

ISSN : 2228-7477